NASDAQ$KURA
Kura Oncology Inc · Q2 2024 earnings
Q2 2024 earnings · · After market close · Investor relations
Briefing
Kura Oncology Inc reported increased operating expenses and a larger net loss for Q2 2024 compared to the prior year.
Kura Oncology, a clinical-stage biopharmaceutical company, reported a net loss of $50.8 million for the three months ended June 30, 2024, driven by higher research and development costs for its ziftomenib and other pipeline programs. The company maintained a strong cash position of $491.5 million including short-term investments, supporting ongoing clinical trials. Key advancements included completion of enrollment in the Phase 2 portion of the KOMET-001 trial with topline data expected in early 2025.
- R&D expenses rose 41% year-over-year to $39.7 million, primarily due to ziftomenib clinical development.
- Net loss per share was $(0.59) on a basic and diluted basis, compared to $(0.53) in Q2 2023.
- Cash and cash equivalents increased to $45.2 million, with total liquidity at $491.5 million including short-term investments.
- Company completed enrollment of 85 patients in Phase 2 KOMET-001 and received Breakthrough Therapy Designation for ziftomenib in NPM1-mutant AML.
Headline financials
Revenue & EPS history
Kura Oncology · Revenue · Quarterly
$0
Forward guidance
Company expects to report topline data from KOMET-001 in early 2025 and present updated KOMET-007 data in Q4 2024; plans to initiate Phase 1 study in GIST in H1 2025.
Tailwinds
- Breakthrough Therapy Designation received for ziftomenib
- Strong liquidity position extending runway into 2027
- Multiple ongoing combination studies advancing
Headwinds
- Continued net losses expected as pipeline advances
- No product revenue until potential future approval
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports
+0.5%
Avg return
Earnings day
+1.3%
Avg return
5 days after
+0.9%
Avg return
30 days after
53%
21 / 40 earnings
Positive
+22.4%
Q2 2016
Best reaction
-19.3%
Q4 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2024 | — | — | — | |
| Q1 2026 | +1.7% | -2.9% | -6.8% | |
| Q4 2025 | -0.5% | +8.3% | +0.7% | |
| Q3 2025 | +2.0% | +0.9% | +22.6% | |
| Q2 2025 | -7.0% | +8.9% | +37.9% | |
| Q1 2025 | -0.6% | -13.0% | -12.3% | |
| Q4 2024 | -1.5% | -5.7% | -9.3% | |
| Q3 2024 | -0.9% | +4.1% | -40.2% | |
| Q1 2024 | +1.7% | +3.9% | +1.6% | |
| Q4 2023 | +3.1% | +4.1% | +2.8% | |
| Q3 2023 | +12.8% | +16.0% | +24.7% | |
| Q2 2023 | +7.1% | +1.3% | -2.0% | |
| Q1 2023 | +8.8% | +11.1% | +14.6% | |
| Q4 2022 | -2.2% | -0.3% | -1.4% | |
| Q3 2022 | -7.2% | -14.8% | +2.6% | |
| Q2 2022 | +1.1% | +4.2% | -0.8% | |
| Q1 2022 | -11.8% | -22.5% | -8.7% | |
| Q4 2021 | +14.6% | +13.6% | +12.9% | |
| Q3 2021 | +6.5% | +0.2% | -32.6% | |
| Q2 2021 | +0.8% | -3.4% | +8.0% | |
| Q1 2021 | +2.5% | -1.5% | -16.6% | |
| Q4 2020 | -19.3% | -10.0% | -17.8% | |
| Q3 2020 | +9.2% | +20.0% | +12.3% | |
| Q2 2020 | +15.7% | +17.0% | +36.7% | |
| Q1 2020 | +5.3% | +7.0% | +18.1% | |
| Q4 2019 | -4.3% | -3.8% | -26.1% | |
| Q3 2019 | -4.4% | +1.1% | -1.0% | |
| Q2 2019 | +0.8% | -1.2% | -20.6% | |
| Q1 2019 | +5.9% | +4.1% | +3.0% | |
| Q4 2018 | -9.0% | -1.7% | +12.3% | |
| Q3 2018 | +5.4% | +9.4% | +19.3% | |
| Q2 2018 | -13.7% | -11.2% | -7.0% | |
| Q1 2018 | -0.6% | +4.7% | +3.5% | |
| Q4 2017 | -1.3% | -13.5% | -23.8% | |
| Q3 2017 | -6.4% | +11.1% | -4.4% | |
| Q2 2017 | -13.0% | -38.2% | -32.9% | |
| Q1 2017 | +0.0% | +2.8% | -13.9% | |
| Q4 2016 | -8.5% | -6.3% | +6.9% | |
| Q3 2016 | +6.0% | +25.3% | +27.7% | |
| Q2 2016 | +22.4% | +20.1% | +43.5% | |
| Q4 2015 | +0.5% | — | — | |
| Q4 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — | |
| Q2 2012 | — | — | — | |
| Q1 2012 | — | — | — | |
| Q4 2011 | — | — | — | |
| Q3 2011 | — | — | — | |
| Q2 2011 | — | — | — | |
| Q1 2011 | — | — | — | |
| Q4 2010 | — | — | — | |
| Q3 2010 | — | — | — | |
| Q2 2010 | — | — | — | |
| Q1 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro